How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analyst estimates of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%. During the same period in the previous year, the company posted $0.09 EPS.

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX) , Eldorado Gold (EGO) , NVIDIA (NVDA) , Inovio Pharmaceuticals (INO) , Synergy Pharmaceuticals (SGYP) , JD.com (JD) , Baidu (BIDU) , ACADIA Pharmaceuticals (ACAD) , Advanced Micro Devices (AMD) and Alibaba Group (BABA) .

NASDAQ:BDSI

BioDelivery Sciences International (BDSI) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free BDSI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $5.59
▼
$5.60
50-Day Range: $5.54
▼
$5.60
52-Week Range: $2.50
▼
$5.62

Volume: 2.09 million shs
Average Volume: 3.34 million shs
Market Capitalization: $577.05 million

P/E Ratio: 6.74
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BioDelivery Sciences International alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About BioDelivery Sciences International Stock (NASDAQ:BDSI)

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

BDSI Stock News Headlines

September 14, 2023 | usnews.com

Florida International University

May 6, 2023 | usnews.com

International High School for Health Sciences

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

October 15, 2022 | omaha.com

International climate change bodies win humanity award

September 16, 2022 | thestreet.com

Perilous Reversal Watch: BioDelivery Sciences International (BDSI)

September 13, 2022 | npr.org

Science

May 10, 2022 | seekingalpha.com

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript

May 2, 2022 | thestreet.com

Jim Cramer's Top Stock Picks: DF MNST BDSI

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 5, 2022 | benzinga.com

Why Collegium Pharmaceutical's Shares Are Trading Higher Today

February 24, 2022 | finance.yahoo.com

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

February 24, 2022 | seekingalpha.com

BioDelivery Sciences launches migraine therapy in U.S.

February 24, 2022 | finance.yahoo.com

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

February 15, 2022 | stockhouse.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout

February 14, 2022 | apnews.com

BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders

February 14, 2022 | apnews.com

BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders

February 14, 2022 | finance.yahoo.com

BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium

February 7, 2022 | finance.yahoo.com

Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)

February 6, 2022 | nasdaq.com

BioDelivery Sciences International (NASDAQ:BDSI) Could Easily Take On More Debt

January 31, 2022 | finance.yahoo.com

Should Value Investors Pick BioDelivery (BDSI) Stock Now?

December 28, 2021 | finance.yahoo.com

Raleigh pharma gets favorable ruling in case for drug exclusivity

December 20, 2021 | fool.com

Why BioDelivery Sciences International Stock Was Up 28.5% Monday

December 3, 2021 | finance.yahoo.com

Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?

November 17, 2021 | finance.yahoo.com

BioDelivery Sciences International, Inc. (BDSI)

November 15, 2021 | finance.yahoo.com

Biodelivery Sciences Intl Insider Makes $320K Stock Purchase

November 9, 2021 | nasdaq.com

Tuesday 11/9 Insider Buying Report: BDSI, BALY

November 3, 2021 | finance.yahoo.com

BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates

See More Headlines

Receive BDSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:BDSI
CUSIP: 09060J10
CIK: 1103021
Web: www.bdsi.com
Phone: (919) 582-9050
Fax: 919-582-9051
Employees: 200
Year Founded: 1997

Profitability

EPS (Most Recent Fiscal Year): $0.83
Trailing P/E Ratio: 6.74
Forward P/E Ratio: 14.71
P/E Growth: N/A
Net Income: $84.86 million
Net Margins: 50.90%
Pretax Margin: 17.77%
Return on Equity: 21.25%
Return on Assets: 10.56%

Debt

Debt-to-Equity Ratio: 0.29
Current Ratio: 2.45
Quick Ratio: 2.17

Sales & Book Value

Annual Sales: $166.70 million
Price / Sales: 3.46
Cash Flow: $0.36 per share
Price / Cash Flow: 15.42
Book Value: $1.90 per share
Price / Book: 2.94

Miscellaneous

Outstanding Shares: 103,229,000
Free Float: 92,927,000
Market Cap: $577.05 million
Optionable: Optionable
Beta: 0.56

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Jeffrey Allen Bailey (Age 59)
CEO & Director
Comp: $599.96k
Mr. Scott M. Plesha (Age 57)
Pres & Chief Commercial Officer
Comp: $629.46k
Mr. James Vollins J.D. (Age 53)
Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Comp: $586.68k
Dr. Thomas B. Smith FAAFP (Age 61)
M.D., Chief Medical Officer
Comp: $570.06k
Mr. John Golubieski (Age 57)
CFO & Chief Accounting Officer
Mr. Joseph M. Lockhart
Sr. VP of Operations
Mr. Kevin Ostrander
Sr. VP of Bus. Devel.
Dr. Bill McCarberg
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
Dr. Arthur G. Lipman PharmD
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
Dr. Jeff Katz
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board

Key Competitors

View All Competitors

BDSI Stock Analysis - Frequently Asked Questions

How were BioDelivery Sciences International's earnings last quarter?: BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analyst estimates of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%. During the same period in the previous year, the company posted $0.09 EPS.
What other stocks do shareholders of BioDelivery Sciences International own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

This page (NASDAQ:BDSI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioDelivery Sciences International (BDSI) Stock Price, News & Analysis

About BioDelivery Sciences International Stock (NASDAQ:BDSI)

BDSI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

BDSI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info